XML 51 R41.htm IDEA: XBRL DOCUMENT
v3.24.3

Description of Business and Significant Accounting Policies - Additional Information (Detail) € in Millions, $ in Millions |  | 1 Months Ended | 9 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | ---
Jun. 27, 2024 | Dec. 31, 2023 USD ($) | Jan. 31, 2022 USD ($) | Jun. 30, 2021 USD ($) | Sep. 30, 2024 USD ($) Segment | Sep. 30, 2024 EUR (€) | Jun. 30, 2024 USD ($) | Jul. 01, 2013 USD ($)
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] |  |  |  |  |  |  |  |
Percentage of future royalties |  |  |  |  | 1.00% |  |  |
Number of operating segment | Segment |  |  |  |  | 1 |  |  |
Loss on purchase commitments | € |  |  |  |  |  | € 56.6 |  |
Sagard |  |  |  |  |  |  |  |
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] |  |  |  |  |  |  |  |
Percentage of royalty on net sales |  |  |  |  | 1.00% |  |  |
Percentage of royalty on future net sales |  | 1.00% |  |  |  |  |  |
Insulin |  |  |  |  |  |  |  |
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] |  |  |  |  |  |  |  |
Loss on purchase commitments |  | $ 64.8 |  |  | $ 62.6 |  |  |
Tyvaso DPI |  |  |  |  |  |  |  |
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] |  |  |  |  |  |  |  |
Percentage of royalty on net sales |  |  |  |  | 10.00% |  |  |
Percentage of royalty on future net sales |  |  |  |  | 9.00% |  |  |
Percentage of royalty on net revenue |  |  |  |  | 10.00% |  |  |
Percentage of future royalties |  |  |  |  | 9.00% |  |  |
Maximum | AFREZZA product sales |  |  |  |  |  |  |  |
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] |  |  |  |  |  |  |  |
Sales return right following product expiration in months |  |  |  |  | 12 months |  |  |
Minimum | AFREZZA product sales |  |  |  |  |  |  |  |
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] |  |  |  |  |  |  |  |
Sales return right following product expiration in months |  |  |  |  | 6 months |  |  |
Convertible Promissory Note | Thirona Bio, Inc. |  |  |  |  |  |  |  |
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] |  |  |  |  |  |  |  |
Increased interest rate | 10.00% |  |  |  |  |  |  |
Principal amount |  |  |  |  | $ 8.0 |  | $ 8.0 |
Purchase of available-for-sale securities |  |  | $ 5.0 | $ 3.0 |  |  |  |
Interest rate |  |  |  | 6.00% |  |  |  |
MidCap Credit Facility |  |  |  |  |  |  |  |
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] |  |  |  |  |  |  |  |
Principal amount |  | $ 33.3 |  |  |  |  |  |
Milestone Rights Liability | Deerfield |  |  |  |  |  |  |  |
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] |  |  |  |  |  |  |  |
Contingent liability remain payable |  |  |  |  |  |  |  | $ 50.0
Milestone Rights Liability | Maximum | Deerfield |  |  |  |  |  |  |  |
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] |  |  |  |  |  |  |  |
Contingent liability for milestone payments |  |  |  |  |  |  |  | $ 90.0

X
- Definition Contingent Liability + References No definition available. + Details
Name: | mnkd_ContingentLiability
Namespace Prefix: | mnkd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contingent liability remaining payable amount. + References No definition available. + Details
Name: | mnkd_ContingentLiabilityRemainingPayableAmount
Namespace Prefix: | mnkd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Organization, consolidation and presentation of financial statements disclosure. + References No definition available. + Details
Name: | mnkd_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems
Namespace Prefix: | mnkd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of future royalties. + References No definition available. + Details
Name: | mnkd_PercentageOfFutureRoyalties
Namespace Prefix: | mnkd_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of royalty on future net sales. + References No definition available. + Details
Name: | mnkd_PercentageOfRoyaltyOnFutureNetSales
Namespace Prefix: | mnkd_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of royalty on net revenue. + References No definition available. + Details
Name: | mnkd_PercentageOfRoyaltyOnNetRevenue
Namespace Prefix: | mnkd_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of royalty on net sales. + References No definition available. + Details
Name: | mnkd_PercentageOfRoyaltyOnNetSales
Namespace Prefix: | mnkd_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Purchase of available-for-sale securities. + References No definition available. + Details
Name: | mnkd_PurchaseOfAvailableForSaleSecurities
Namespace Prefix: | mnkd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Sales return period. + References No definition available. + Details
Name: | mnkd_SalesReturnPeriod
Namespace Prefix: | mnkd_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Face (par) amount of debt instrument at time of issuance. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details
Name: | us-gaap_DebtInstrumentFaceAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Incremental percentage increase (decrease) in the stated rate on a debt instrument. + References No definition available. + Details
Name: | us-gaap_DebtInstrumentInterestRateIncreaseDecrease
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Rate of interest on investment. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details
Name: | us-gaap_InvestmentInterestRate
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details
Name: | us-gaap_NumberOfOperatingSegments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. + References No definition available. + Details
Name: | us-gaap_PurchaseObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | dei_LegalEntityAxis=mnkd_SagardHealthcarePartnersFundingBorrowerSPE2LPMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mnkd_InsulinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mnkd_TyvasoDPIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=mnkd_ConvertiblePromissoryNoteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnkd_ThironaBioIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CreditFacilityAxis=mnkd_MidCapCreditFacilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CreditFacilityAxis=mnkd_MilestoneRightsLiabilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=mnkd_DeerfieldManagementCompanyLpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |